3 papers
q-bio.BM2026
Latent-Y: A Lab-Validated Autonomous Agent for De Novo Drug Design
Latent Labs Team, Sebastian M. Schmon, Daniella Pretorius +17
Drug discovery relies on iterative expert workflows that are slow to parallelize and difficult to scale. Here we introduce Latent-Y, an AI agent that autonomously executes complete…
q-bio.BM2025
Latent-X: An Atom-level Frontier Model for De Novo Protein Binder Design
Latent Labs Team, Alex Bridgland, Jonathan Crabbé +13
Traditional drug discovery relies on rounds of screening millions of candidate molecules with low success rates, making drug discovery time and resource intensive. To overcome this…
q-bio.BM2024
ABodyBuilder3: Improved and scalable antibody structure predictions
Henry Kenlay, Frédéric A. Dreyer, Daniel Cutting +2
Accurate prediction of antibody structure is a central task in the design and development of monoclonal antibodies, notably to understand both their developability and their bindin…